These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

516 related articles for article (PubMed ID: 17962372)

  • 1. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system.
    Feng B; Mills JB; Davidson RE; Mireles RJ; Janiszewski JS; Troutman MD; de Morais SM
    Drug Metab Dispos; 2008 Feb; 36(2):268-75. PubMed ID: 17962372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
    Mahar Doan KM; Humphreys JE; Webster LO; Wring SA; Shampine LJ; Serabjit-Singh CJ; Adkison KK; Polli JW
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1029-37. PubMed ID: 12438524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport.
    Varma MV; Sateesh K; Panchagnula R
    Mol Pharm; 2005; 2(1):12-21. PubMed ID: 15804173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
    Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
    J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
    Taub ME; Podila L; Ely D; Almeida I
    Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First characterization of fish P-glycoprotein (abcb1) substrate specificity using determinations of its ATPase activity and calcein-AM assay with PLHC-1/dox cell line.
    Zaja R; Lončar J; Popovic M; Smital T
    Aquat Toxicol; 2011 May; 103(1-2):53-62. PubMed ID: 21392495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of unbound plasma drug levels and P-glycoprotein transport data in prediction of central nervous system exposure.
    He H; Lyons KA; Shen X; Yao Z; Bleasby K; Chan G; Hafey M; Li X; Xu S; Salituro GM; Cohen LH; Tang W
    Xenobiotica; 2009 Sep; 39(9):687-93. PubMed ID: 19569734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
    Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain.
    Summerfield SG; Stevens AJ; Cutler L; del Carmen Osuna M; Hammond B; Tang SP; Hersey A; Spalding DJ; Jeffrey P
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1282-90. PubMed ID: 16330496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.
    Rautio J; Humphreys JE; Webster LO; Balakrishnan A; Keogh JP; Kunta JR; Serabjit-Singh CJ; Polli JW
    Drug Metab Dispos; 2006 May; 34(5):786-92. PubMed ID: 16455806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux.
    Dai H; Marbach P; Lemaire M; Hayes M; Elmquist WF
    J Pharmacol Exp Ther; 2003 Mar; 304(3):1085-92. PubMed ID: 12604685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier.
    Wang Q; Rager JD; Weinstein K; Kardos PS; Dobson GL; Li J; Hidalgo IJ
    Int J Pharm; 2005 Jan; 288(2):349-59. PubMed ID: 15620875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery.
    Schwab D; Fischer H; Tabatabaei A; Poli S; Huwyler J
    J Med Chem; 2003 Apr; 46(9):1716-25. PubMed ID: 12699389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rational use of in vitro P-glycoprotein assays in drug discovery.
    Polli JW; Wring SA; Humphreys JE; Huang L; Morgan JB; Webster LO; Serabjit-Singh CS
    J Pharmacol Exp Ther; 2001 Nov; 299(2):620-8. PubMed ID: 11602674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polarized P-glycoprotein expression by the immortalised human brain endothelial cell line, hCMEC/D3, restricts apical-to-basolateral permeability to rhodamine 123.
    Tai LM; Reddy PS; Lopez-Ramirez MA; Davies HA; Male DK; Loughlin AJ; Romero IA
    Brain Res; 2009 Oct; 1292():14-24. PubMed ID: 19631619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
    Gnoth MJ; Sandmann S; Engel K; Radtke M
    Drug Metab Dispos; 2010 Aug; 38(8):1341-6. PubMed ID: 20413726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro P-glycoprotein efflux ratio can predict the in vivo brain penetration regardless of biopharmaceutics drug disposition classification system class.
    Kikuchi R; de Morais SM; Kalvass JC
    Drug Metab Dispos; 2013 Dec; 41(12):2012-7. PubMed ID: 24009309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 3 assay systems using a common probe substrate, calcein AM, for studying P-gp using a selected set of compounds.
    Szerémy P; Pál A; Méhn D; Tóth B; Fülöp F; Krajcsi P; Herédi-Szabó K
    J Biomol Screen; 2011 Jan; 16(1):112-9. PubMed ID: 21057029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio.
    Ohe T; Sato M; Tanaka S; Fujino N; Hata M; Shibata Y; Kanatani A; Fukami T; Yamazaki M; Chiba M; Ishii Y
    Drug Metab Dispos; 2003 Oct; 31(10):1251-4. PubMed ID: 12975334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception.
    Kalvass JC; Olson ER; Pollack GM
    Drug Metab Dispos; 2007 Mar; 35(3):455-9. PubMed ID: 17178769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.